432 related articles for article (PubMed ID: 27140397)
1. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
[TBL] [Abstract][Full Text] [Related]
2. Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation.
Zhou X; Li JW; Chen Z; Ni W; Li X; Yang R; Shen H; Liu J; DeMayo FJ; Lu J; Kaye FJ; Wu L
Elife; 2021 Jun; 10():. PubMed ID: 34142658
[TBL] [Abstract][Full Text] [Related]
3. The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non-small cell lung cancer.
Rodón L; Svensson RU; Wiater E; Chun MGH; Tsai WW; Eichner LJ; Shaw RJ; Montminy M
Sci Adv; 2019 Jul; 5(7):eaaw6455. PubMed ID: 31355336
[TBL] [Abstract][Full Text] [Related]
4. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
Yang R; Li SW; Chen Z; Zhou X; Ni W; Fu DA; Lu J; Kaye FJ; Wu L
J Natl Cancer Inst; 2019 Jul; 111(7):664-674. PubMed ID: 30423141
[TBL] [Abstract][Full Text] [Related]
5. CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells.
Chen Z; Lin S; Li JL; Ni W; Guo R; Lu J; Kaye FJ; Wu L
Oncogene; 2018 Apr; 37(14):1885-1895. PubMed ID: 29353885
[TBL] [Abstract][Full Text] [Related]
6. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
7. MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway.
Yu T; Zhao Y; Hu Z; Li J; Chu D; Zhang J; Li Z; Chen B; Zhang X; Pan H; Li S; Lin H; Liu L; Yan M; He X; Yao M
Cancer Res; 2017 Nov; 77(21):5782-5794. PubMed ID: 28923857
[TBL] [Abstract][Full Text] [Related]
8. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
9. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer.
Zang C; Nie FQ; Wang Q; Sun M; Li W; He J; Zhang M; Lu KH
Oncotarget; 2016 Mar; 7(10):11696-707. PubMed ID: 26840083
[TBL] [Abstract][Full Text] [Related]
11. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
12. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.
Li W; Sun M; Zang C; Ma P; He J; Zhang M; Huang Z; Ding Y; Shu Y
Cell Death Dis; 2016 May; 7(5):e2225. PubMed ID: 27195672
[TBL] [Abstract][Full Text] [Related]
13. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
15. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
16. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
17. The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
Wei CC; Nie FQ; Jiang LL; Chen QN; Chen ZY; Chen X; Pan X; Liu ZL; Lu BB; Wang ZX
Oncotarget; 2017 Jan; 8(3):5233-5246. PubMed ID: 28029651
[TBL] [Abstract][Full Text] [Related]
18. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
[TBL] [Abstract][Full Text] [Related]
19. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
